Please assess the completion status of the following clinical trial:

Trial Title: VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* In overall general good health.~* HSV-2 (Herpes Simplex Virus-2) seropositive at screening.~Exclusion criteria:~* have active lesions consistent with genital herpes.~* previous history of symptomatic genital herpes.~* history of recurrent, undiagnosed symptoms consistent with genital herpes.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Sequence 1: VALTREX 1 g once daily, Placebo (Type: EXPERIMENTAL): VALTREX 1 g once daily, Placebo
- Sequence 2: Placebo, VALTREX 1 g once daily (Type: EXPERIMENTAL): Placebo, VALTREX 1 g once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).